A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.
2/5 보강
TL;DR
DPYD sequencing identified additional relevant variants and improved the sensitivity of DPYD testing, which revealed that carriers of deleterious DPYD variants exhibited significantly longer overall survival in CRC patients.
OpenAlex 토픽 ·
Colorectal Cancer Treatments and Studies
Genetic factors in colorectal cancer
Lung Cancer Treatments and Mutations
DPYD sequencing identified additional relevant variants and improved the sensitivity of DPYD testing, which revealed that carriers of deleterious DPYD variants exhibited significantly longer overall s
- OR 1.93
- HR 0.65
APA
Valérie Boige, Estelle Menoret, et al. (2026). A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.. Journal of the National Cancer Institute, 118(4), 699-710. https://doi.org/10.1093/jnci/djaf357
MLA
Valérie Boige, et al.. "A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.." Journal of the National Cancer Institute, vol. 118, no. 4, 2026, pp. 699-710.
PMID
41386266 ↗
Abstract 한글 요약
[BACKGROUND] Deleterious DPYD variants are the primary identified cause of severe fluoropyrimidine-related toxicity. The objective was to improve the sensitivity of current DPYD genotyping recommendations and develop a predictive model for severe toxicity.
[METHODS] This pooled analysis included colorectal cancer (CRC) patients from 7 prospective studies. Full DPYD sequencing was performed. Depending on their minor allele frequency (MAF), relevant DPYD variants were identified using Bolasso, or SKAT coupled with in silico functionality predictions. The primary end-point was 12-week grade 4-5 fluoropyrimidine-related hematological and digestive toxicities. Multivariate logistic regression models were developed.
[RESULTS] Of 4496 eligible patients, 3437 were analyzed (267 events). The final model included patient/treatment characteristics, variants *2A/*13/p.D949V, common variants rs1801160 (p.V732I [*6], OR = 1.93, 95% CI = 1.37 to 2.70 if heterozygous) and rs2297595 (p.M166V, OR = 1.49, 95% CI = 1.13 to 1.96 if heterozygous), and aggregation of all very rare (MAF < 0.01) in silico-predicted deleterious variants (OR = 3.20, 95% CI = 1.43 to 7.14 if one allele). Model performance was supported by discrimination (AUC = 0.76, 95% CI = 0.73 to 0.78), calibration, and internal validation. Crude sensitivity of DPYD testing increased from 11.2% for *2A/*13/p.D949V to 47.5% when including the 44 variants. An exploratory analysis of 1138 stage III CRC patients revealed, for the first time, that carriers of deleterious DPYD variants exhibited significantly longer overall survival: HR = 0.65, 95% CI = 0.43 to 0.98 for p.V732I and HR = 0.62, 95% CI = 0.43 to 0.90 for p.M166V.
[CONCLUSION] DPYD sequencing identified additional relevant variants and improved the sensitivity of DPYD testing. An online calculator (https://fluoropyrimidine-toxicity-predictor.gustaveroussy.fr/) is provided to estimate the individual probability of developing life-threatening toxicity, based on clinical covariates and extended DPYD genotype.
[METHODS] This pooled analysis included colorectal cancer (CRC) patients from 7 prospective studies. Full DPYD sequencing was performed. Depending on their minor allele frequency (MAF), relevant DPYD variants were identified using Bolasso, or SKAT coupled with in silico functionality predictions. The primary end-point was 12-week grade 4-5 fluoropyrimidine-related hematological and digestive toxicities. Multivariate logistic regression models were developed.
[RESULTS] Of 4496 eligible patients, 3437 were analyzed (267 events). The final model included patient/treatment characteristics, variants *2A/*13/p.D949V, common variants rs1801160 (p.V732I [*6], OR = 1.93, 95% CI = 1.37 to 2.70 if heterozygous) and rs2297595 (p.M166V, OR = 1.49, 95% CI = 1.13 to 1.96 if heterozygous), and aggregation of all very rare (MAF < 0.01) in silico-predicted deleterious variants (OR = 3.20, 95% CI = 1.43 to 7.14 if one allele). Model performance was supported by discrimination (AUC = 0.76, 95% CI = 0.73 to 0.78), calibration, and internal validation. Crude sensitivity of DPYD testing increased from 11.2% for *2A/*13/p.D949V to 47.5% when including the 44 variants. An exploratory analysis of 1138 stage III CRC patients revealed, for the first time, that carriers of deleterious DPYD variants exhibited significantly longer overall survival: HR = 0.65, 95% CI = 0.43 to 0.98 for p.V732I and HR = 0.62, 95% CI = 0.43 to 0.90 for p.M166V.
[CONCLUSION] DPYD sequencing identified additional relevant variants and improved the sensitivity of DPYD testing. An online calculator (https://fluoropyrimidine-toxicity-predictor.gustaveroussy.fr/) is provided to estimate the individual probability of developing life-threatening toxicity, based on clinical covariates and extended DPYD genotype.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.